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pathways for biopharmaceuticals are well established, it is only in the past decade that 
regulatory development has evolved to secure guidelines and controls for stem cell 
based therapies, creating evaluation challenges for payers as these agents enter the 
market. METHODS: Conventional pharmaceuticals are generally assessed using a 
“value based” approach, in which their value is assessed by evaluating the positive 
and negative differentiation from established references. As no true direct reference 
will be available for allogenic products, potential references will be identiﬁed to 
support the “value based” approach and identify market access challenges. RESULTS: 
Skin replacement therapies are the only commercialized allogenic products to date 
(e.g. TransCyte and Apligraf), and serve as interesting case studies to evaluate how 
these types of therapies may be valued. Biologic agents faced a similar dilemma when 
ﬁrst launched and demonstrated the importance of identifying appropriate indirect 
references to support these novel drugs. CONCLUSIONS: In the evolving regulatory 
and P&R environment, a greater unknown in regenerative based medicine surrounds 
the process of pricing and market access. Learning from biologics and skin replace-
ment therapies can infer challenges and opportunities for these new therapies.
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BACKGROUND: In The Netherlands, the reimbursement of new drugs is not 
only based on their therapeutic value and budget impact but also on their cost-effec-
tiveness. Since 1 January 2005, economic evaluations are formally required for estab-
lishing cost-effectiveness. These evaluations should follow pharmacoeconomic 
guidelines. OBJECTIVES: This study reviews: 1) the extent to which guidelines are 
followed in pharmacoeconomic evaluations; 2) the use of guidelines in assessing the 
evaluations and cost-effectiveness of drugs; and 3) the role of pharmacoeconomics in 
reimbursement advises and decisions. METHODS: All reimbursement ﬁles that were 
submitted and assessed between 1 January 2005 and 1 October 2008 are reviewed 
(n  21). Information on the follow-up and use of pharmacoeconomic guidelines as 
well as the advises and decisions on drug reimbursement is extracted from publicly 
available sources by two independent reviewers. Both quantitative and qualitative 
descriptive analyses are conducted. RESULTS: Formally required pharmacoeconomic 
evaluations increasingly follow guidelines, particularly those concerning the analytic 
perspective (81%), the relevant comparators (81%) and both the total and incremental 
comparative analyses (100%). Due to ﬂaws in drug indication, type of analysis 
and time horizon, however, the cost-effectiveness of drugs is not always well estab-
lished (62%). Moreover, the costs and effects are not always correctly analysed and 
modelling studies are often non-transparent. Partly based on pharmacoeconomics, 12 
new drugs are reimbursed, and 9 rejected. CONCLUSIONS: Cost-effectiveness of 
new drugs and sound pharmacoeconomic evaluations become increasingly important 
in drug reimbursement and ensuring the quality and affordability of Dutch pharma-
ceutical care.
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OBJECTIVES: Despite a growth in the total number of physicians in many industrial-
ized countries, signiﬁcant inequalities in their distribution exist between rural and        
urban areas. Therefore, decision-makers need detailed information about young 
physicians’ preferences in establishing a practice. The aim of the study was to quantify 
the preferences for different attributes relevant to practice establishment in Germany. 
METHODS: In the qualitative part of the study, in-depth interviews of 22 physicians 
were conducted to identify relevant practice attributes. Based on this information 
a questionnaire was developed containing a discrete choice experiment comprised      
of a “best-worst scaling” (BWS) task. It was mailed to a representative sample of 
14,939 young physicians who were close to make a decision regarding practice estab-
lishment. Regression analysis was used to estimate utility weights quantifying physi-
cians’ preferences for practice attributes. RESULTS: From the qualitative part six 
attributes were identiﬁed relevant to practice establishment: “professional coopera-
tion”, “income”, “career opportunities of the partner”, “availability of child care”,     
“leisure activities”, and “on-call duty”. For the BWS task, 5026 returned question-
naires were analyzed. The results indicated that a change in income is most important 
to physicians. It would result in the largest utility change compared with changes in 
the remaining attributes. Physicians’ preferences showed that the additional net 
income per month to compensate the disutility of a practice in a rural area was a9044 
(US$11,938). Yet, non-monetary attributes as on-site availability of childcare and few           
on-call duty would decrease the additional income required to compensate the disutil-
ity of a rural practice. CONCLUSIONS: The results offer detailed and quantiﬁable 
information to health policy makers to develop tailored incentive-based interventions   
to diminish urban-rural inequalities in physician coverage. Only a substantial rise in 
income increases the probability that young physicians establish a practice in more 
rural area.
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OBJECTIVES: Identify the health agencies/committees that are involved in new drug 
evaluations in Spain. METHODS: Search in the Spanish Health System and in the 
several Regional Health Systems databases the different agencies/committees that are 
developing new drug evaluations. RESULTS: Five regional drug evaluation commit-
tees which are working since late 2003 in a coordinated way are playing the main 
role of new drugs evaluations in the primary care (PC) setting, conforming a Joint 
Committe. Other 12 regions are publishing with different degrees of periodicity their 
own new drug information leaﬂets in the PC setting. In the hospital setting each centre 
has been autonomous for accepting or rejecting new drug applications into their own 
formularies, although there is a working group in the SEFH (Spanish Society of Hos-
pital Pharmacy), named GENESIS, which is leading an initiative to have a common 
methodology for evaluating new drugs and to avoiding potential duplicities in drug 
evaluations in the hospital background. Besides, there are 7 different health technology 
agencies (1 national  6 regional) in Spain that rarely evaluate new drugs. CONCLU-
SIONS: Spain has one of the biggest European framework of health technology agen-
cies that is seldom used to develop new drug evaluations. In parallel, all the Regional 
Health Systems have developed their own new drug evaluation entities to evaluate 
drugs with a high potential consumption in the PC setting. Other initiatives have been 
developed to disminish potential evaluation duplicities either in the PC or in the hos-
pital setting. Most of the new drugs evaluations are negative and focused to restrict 
the consumption of new drugs available in the market to control drug expenditure.
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OBJECTIVES: Regular monitoring of drug consumption is an important tool for plan-
ning and policy making in rational use of drugs. This study has evaluated the general 
practitioners’ prescriptions indicators’ trends in prescriptions during 1998–2003 
periods. METHODS: In this ecologic study, over 8 million prescriptions from the data 
bank of National Committee of Rational Drug Use (NCRUD) of Iran were analyzed. 
Mean items per prescription, mean cost of prescription, percentage of prescript paren-
teral drugs, percentage of prescript antimicrobial drugs, percentage of prescript Non- 
Steroidal Anti Inﬂammatory Drugs (NSAIDs) and percentage of prescript corticosteroid 
drugs were calculated quarterly from 1998 to 2003. Time series analysis by using 
appropriate regression models was performed with SPSS software version 11.5. 
RESULTS: Mean items per prescription shows descending trend during the study 
period. This indicator decreased from 4.9 in 1998 to 3.07 in 2003. Linear regression 
model predicted 0.037 decrease for this indicator per each season. Percentage of pre-
script antimicrobial drugs had an ascending pattern at ﬁrst, following with a descending 
trend. Injectable drugs prescription decreased from 52.2% in the spring of 1998 to 
45.5% in the fall 2003. NSAIDs prescription had 0.37% decrease per season. CON-
CLUSIONS: Observed descending trends of the study indicators shows the effective-
ness of NCRUD committees’ activities and it is suggested to promote their activities.
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OBJECTIVES: Evaluation of the drug use is a system of continuous, systematic, cri-
teria-based drug evaluation that ensures the appropriate use of drugs. Drug utilization 
research in itself does not necessarily provide answers, but it contributes to rational 
drug use. Antipsychotics are used to treat the symptoms of schizophrenia and bipolar 
disorders. A review of the cost and consumption for all medicines and antipsychotics 
in Croatia, as well as the data on medicine usage for these two groups are obtained. 
Collecting and analyzing the data on antipsychotic consumption may lead to the 
improvement of the antipsychotic therapy. METHODS: Agency for Medicinal Prod-
ucts and Medical Devices in Croatia collected and processed data on consumption of 
the medicines. Data on medicines usage between 2005–2007 was gathered, processed 
by the DDD/1000 inh/day and ATC classiﬁcation, and analyzed according to the 
ﬁnancial indicators. RESULTS: The total medicines market in Croatia in 2005 was 
a520 million, in 2006 market was a562 million and in 2007 it was a564 million. By 
processing consumption data as DDD, between 2005–2007 consumption of N05A 
group the result was 8.30, 9.56 and 9.65 DDD/1000 inh/day, respectively. Expendi-
ture of antipsychotic drugs individually was as follows: haloperidol held the ﬁrst place 
with 1.90 DDD/1000 inh/day in 2005, 1.93 in 2006 and 1.94 in 2007. Promazine 
was second with 1.80 DDD/1000 inh/day in 2005, 1.86 in 2006 and third with 1.89 
in 2007. Olanzapine was third with 1.07 DDD/1000 inh/day in 2005, 1.46 in 2006 
and second with 1.92 in 2007. CONCLUSIONS: Within the period of 2005–2007, 
the processed antipsychotics in Croatia showed a continuous increase in prescribed 
DDD/1000 inh/day. Haloperidol, promazine and olanzapine were the most prescribed 
drugs. By collecting and analyzing data useful for the improvement of pharmacother-
apy, we also obtain information for the many other factors essential for the rational 
health care.
